BMRN
BioMarin Pharmaceutical Inc.
$53.57
+$1.66(+3.20%)
61
Overall
80
Value
45
Tech
60
Quality
Market Cap
$10.23B
Volume
3.25M
52W Range
$51.00 - $73.51
Target Price
$95.89
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $889.9M | $1.1B | $1.3B | $1.5B | $1.7B | $1.9B | $1.8B | $2.1B | $2.4B | $2.9B | ||
| Total Revenue | $889.9M | $1.1B | $1.3B | $1.5B | $1.7B | $1.9B | $1.8B | $2.1B | $2.4B | $2.9B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $152.0M | $209.6M | $241.8M | $315.3M | $359.5M | $524.3M | $470.5M | $483.7M | $532.1M | $580.2M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $737.9M | $907.2M | $1.1B | $1.2B | $1.3B | $1.3B | $1.4B | $1.6B | $1.9B | $2.3B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $1.0B | $1.1B | $1.2B | $1.6B | $1.7B | $1.4B | $1.4B | $1.6B | $1.7B | $1.8B | ||
| Research & Development | $634.8M | $661.9M | $610.8M | $696.3M | $715.0M | $628.1M | $628.8M | $649.6M | $746.8M | $747.2M | ||
| Research Expense | $634.8M | $661.9M | $610.8M | $696.3M | $715.0M | $628.1M | $628.8M | $649.6M | $746.8M | $747.2M | ||
| Selling, General & Administrative | $402.3M | $476.6M | $554.3M | $604.4M | $680.9M | $737.7M | $759.4M | $854.0M | $892.4M | $1.0B | ||
| Selling & Marketing Expenses | -- | -- | -- | $315.3M | -- | -- | $30.2M | $25.2M | $27.8M | $34.5M | ||
| General & Administrative Expenses | $402.3M | $476.6M | $554.3M | $604.4M | $680.9M | $737.7M | $759.4M | $854.0M | $892.4M | $1.0B | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | -- | $30.2M | -- | -- | -- | ||
| Salaries & Wages | $11.1M | $11.4M | -- | $315.3M | -- | $20.1M | $20.0M | -- | -- | -- | ||
| Depreciation & Amortization | $50.1M | $73.2M | $75.8M | $90.4M | $89.3M | $43.0M | $46.1M | $38.6M | $62.2M | $43.3M | ||
| Depreciation & Amortization | $50.1M | $73.2M | $75.8M | $90.4M | $89.3M | $43.0M | $46.1M | -- | $62.2M | $43.3M | ||
| Amortization | $684.0M | $553.8M | $517.5M | $491.8M | $456.6M | $-840.0K | -- | $38.1M | $62.2M | $43.3M | ||
| Other Operating Expenses | $9.5M | $-4.9M | $-8.0M | $-2.2M | $-6.9M | $-7.1M | $-11.8M | $2.0M | $38.2M | $4.7M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-110.7M | $-803.4M | $-14.7M | $-123.5M | $-100.5M | $-36.8M | $-82.3M | $149.6M | $185.8M | $484.2M | ||
| EBITDA | $-38.6M | $-663.4M | $130.1M | $28.2M | $45.9M | $83.7M | $47.4M | $271.0M | $314.5M | $654.2M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $38.2M | $39.5M | $42.7M | $43.7M | $23.5M | $27.5M | $14.7M | $15.4M | $17.3M | $12.7M | ||
| Intinc | $4.5M | $7.5M | $14.9M | $22.8M | $22.7M | $16.6M | $10.5M | $18.0M | $58.3M | $74.9M | ||
| Net Non-Operating Interest Income/Expense | $-33.7M | $-32.0M | $-27.9M | $-20.8M | $-712.0K | $-12.7M | $-4.9M | $2.1M | $41.0M | $62.2M | ||
| Gain on Sale of Securities | -- | $-100.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-170.0M | $599.7M | $-123.7M | $-49.4M | $-24.4M | $-59.5M | -- | $101.5M | $12.6M | $-10.0M | ||
| Other Special Charges | $369.5M | $34.4M | $125.0M | $50.0M | $25.0M | -- | -- | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | $-209.6M | $-241.8M | -- | -- | -- | -- | -- | $-38.6M | -- | ||
| Other Impairment Of Capital Assets | $198.7M | $599.1M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-116.5M | $-791.6M | $6.8M | $-99.0M | $-71.4M | $-21.5M | $-60.6M | $165.0M | $205.9M | $554.4M | ||
| Pre-Tax Income | $-154.7M | $-831.0M | $-35.9M | $-142.7M | $-94.8M | $-42.3M | $-75.3M | $149.6M | $188.6M | $541.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $17.1M | $-200.8M | $81.2M | $-65.5M | $-71.0M | $-903.0M | $-11.3M | $8.0M | $20.9M | $114.9M | ||
| NET INCOME | ||||||||||||
| Net Income | $-171.8M | $-630.2M | $-117.0M | $-77.2M | $-23.8M | $854.0M | $-64.1M | $141.6M | $167.6M | $426.9M | ||
| Net Income (Continuing Operations) | $-171.8M | $-630.2M | $-117.0M | $-77.2M | $-23.8M | $859.1M | $-64.1M | $141.6M | $167.6M | $426.9M | ||
| Net Income (Discontinued Operations) | $-171.8M | $-630.2M | $-117.0M | $-77.2M | $-23.8M | $854.0M | $-64.1M | $141.6M | $167.6M | $426.9M | ||
| Net Income (Common Stockholders) | $-207.2M | $-684.1M | $-24.1M | $20.4M | $124.4M | $854.0M | $-64.1M | $141.6M | $167.6M | $426.9M | ||
| Normalized Income | $98.1M | $-223.2M | $218.5M | $-208.2M | $168.7M | $-1.0B | -- | -- | -- | -- | ||
| TOTALS | ||||||||||||
| Total Expenses | $1.2B | $1.3B | $1.4B | $1.9B | $2.1B | $1.9B | $1.8B | $2.1B | $2.3B | $2.4B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $160.0M | $166.0M | $174.4M | $177.1M | $179.0M | $180.8M | $182.9M | $185.3M | $187.8M | $190.0M | ||
| Average Shares Outstanding (Diluted) | -- | $166.2M | $174.4M | $177.3M | $179.0M | $191.7M | $182.9M | $189.0M | $191.6M | $196.7M | ||
| Shares Outstanding | $161.6M | $172.9M | $176.1M | $178.4M | $179.9M | $181.8M | $184.0M | $186.5M | $188.7M | $190.8M | ||
| Basic EPS | $-1.07 | $-3.8 | $-0.67 | $-0.44 | $-0.13 | $4.75 | $-0.35 | $0.76 | $0.89 | $2.25 | ||
| Basic EPS (Continuing Operations) | $-1.07 | $-3.8 | $-0.67 | $-0.44 | $-0.13 | $4.75 | $-0.35 | $0.76 | $0.89 | $2.25 | ||
| Diluted EPS | $-1.07 | $-3.81 | $-0.67 | $-0.44 | $-0.13 | $4.53 | $-0.35 | $0.75 | $0.87 | $2.21 | ||
| Diluted EPS (Continuing Operations) | -- | $-3.81 | $-0.67 | $-0.44 | $-0.13 | $4.53 | $-0.35 | $0.75 | $0.87 | $2.21 | ||
| OTHER METRICS | ||||||||||||
| Acquisition Expense | -- | -- | -- | -- | $359.5M | -- | -- | -- | -- | -- | ||
| Development Expense | -- | -- | -- | -- | -- | -- | $470.5M | -- | -- | -- | ||
| Earnings from equity interest | $-817.0K | $-538.0K | $-1.3M | $-553.0K | $-587.0K | $-6.0K | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-817.0K | $-538.0K | $-1.3M | $-553.0K | $-587.0K | $-6.0K | -- | -- | -- | -- | ||
| Excise Taxes | $152.0M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | $25.0M | $59.5M | -- | $108.0M | -- | $10.0M | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | $524.3M | -- | -- | -- | -- | ||
| Loss And Loss Adjustment Expected Incurred | -- | -- | -- | -- | -- | -- | $470.5M | -- | -- | -- | ||
| Other Gand A | $402.3M | $476.6M | $554.3M | $604.4M | $680.9M | $737.7M | $759.4M | $854.0M | $892.4M | $1.0B | ||
| Other Write Off | -- | -- | -- | -- | -- | $524.3M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $9.3M | $11.6M | $11.4M | $12.2M | -- | -- | -- | -- | -- | -- | ||
| Write Off | -- | $209.6M | $241.8M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BMRN | $53.57 | +3.2% | 3.25M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get BioMarin Pharmaceutical Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW